TB-500 cost in the Netherlands

If you are searching for a price on TB-500 in the Netherlands, the short answer is: no verified retail or reimbursement price exists, because TB-500 has no marketing authorisation in the EU and sits entirely outside the Dutch health insurance system.^[1] What circulates in the Dutch market comes from grey-market vendors operating outside pharmacy regulation. This page explains the regulatory framework behind that absence, what it means for anyone researching the peptide, and where the clinical evidence actually stands.

How the Dutch medicines system works

In the Netherlands, a medicine must hold a marketing authorisation before it can be lawfully placed on the market and sold to patients. For medicines that need EU-wide review, that authorisation comes from the European Medicines Agency (EMA) via the centralised procedure. For medicines reviewed at the national level, it comes from the College ter Beoordeling van Geneesmiddelen (CBG-MEB), the Dutch Medicines Evaluation Board.^[2] The CBG's stated mission is 'good medicines used well', which in practice means it evaluates, monitors and promotes the appropriate use of medicines in the Netherlands.

Thymosin beta-4 and TB-500 appear in neither the EMA register nor the CBG national register. An EMA medicines search for thymosin beta-4, TB-500, RGN-259 or timbetasin (the WHO international non-proprietary name for thymosin beta-4) returns no marketing authorisation, no EPAR, and no referral.^[1] There is no approved thymosin beta-4 product anywhere in the EU at the time of writing.

Why reimbursement is not possible

Reimbursement under the Dutch basic health insurance package (basisverzekering) follows from authorisation. Zorginstituut Nederland, the Dutch Healthcare Institute, assesses whether a medicine belongs in the basic package only after the CBG-MEB or EMA has authorised it. A medicine that has not cleared the authorisation stage never reaches the reimbursement stage. TB-500 has not cleared the first stage, so there is no reimbursement assessment to report, and no contribution from Dutch basic health insurance is possible.

The Farmacotherapeutisch Kompas is the independent prescribing reference maintained by Zorginstituut Nederland for Dutch clinicians. It carries no monograph for thymosin beta-4 or TB-500. Dutch physicians therefore have no official prescribing framework, no authorised dosing guidance, and no approved indication to write a prescription against. Even a willing GP has no regulatory pathway for TB-500 in the Netherlands.

The grey-market supply reality

TB-500 is sold online by vendors who ship to the Netherlands, typically as lyophilised powder in 2 mg or 5 mg vials labelled for research use. These vendors are not Dutch pharmacies operating under Royal Dutch Pharmaceutical Association (KNMP) rules and they are not subject to the identity-testing, labelling or storage requirements that apply to licensed medicines. A 2026 narrative review in Sports Medicine noted that a parallel grey market of unapproved compounds has emerged operating largely outside regulatory oversight, and that rigorous human safety data for compounds such as TB-500 are scarce.^[3]

The grey-market label creates a specific identification problem for TB-500. Vials labelled TB-500 can contain either the synthetic heptapeptide AC-LKKTETQ (CAS 885340-08-9, corresponding to amino acids 17 to 23 of thymosin beta-4, molecular weight approximately 889 daltons) or full-length thymosin beta-4 itself (a 43-residue acetylated peptide, molecular weight approximately 4,963 daltons). These are different molecules. A mass-spectrometry identity check distinguishes them, but grey-market vendors rarely provide that testing, and the label often does not specify which molecule is in the vial.

Why no verified price can be published

No verified pricing data for TB-500 in the Netherlands was available at the time of publication. We do not quote grey-market vendor prices for the following reasons. First, vendor prices change frequently and without notice, so any figure printed here would be unreliable within weeks. Second, because the molecule labelled TB-500 varies between vendors, price comparisons across suppliers are not comparing equivalent products. A lower price may reflect the heptapeptide fragment rather than full-length thymosin beta-4, or it may reflect lower synthesis purity.

Third, and most directly relevant to a Dutch reader: purchasing a substance from an unregulated grey-market vendor is not a pharmacy transaction. The costs go beyond the vial price. They include potential customs examination on importation, no consumer-protection recourse if the product is mislabelled, and no product-liability framework. For a fuller account of these supply-chain considerations, see the TB-500 peptide page, which covers the practical grey-market reality in detail.

What the clinical evidence shows

The preclinical literature on thymosin beta-4 is substantial across rodent models of dermal, cardiac and neurological injury, establishing the biological rationale for wound-healing and tissue-repair effects.^[4] The only Western-standard human trial dataset sits in ophthalmology. The 2023 Phase 3 trial of RGN-259 (a 0.1% thymosin beta-4 ophthalmic solution) in neurotrophic keratopathy randomised 18 patients to treatment or placebo. Complete corneal healing at four weeks occurred in 6 of 10 treated patients versus 1 of 8 on placebo. No significant adverse effects were observed.^[5]

RGN-259 is a topical eye drop. The subcutaneous injection route used by grey-market consumers for soft-tissue injury recovery has not been tested in equivalent human trials. A 2026 review in the American Journal of Sports Medicine stated directly that thymosin beta-4 and its derivative TB-500 promoted angiogenesis and tissue repair in preclinical models but that human orthopaedic data are lacking, and that both remain banned substances in sport.^[6]

The ban in sport has been in effect since 1 January 2018, when USADA confirmed that thymosin-beta4 and its derivatives, including TB-500, were added as examples of prohibited growth factors under section S2.3 of the WADA Prohibited List.^[7] The substance is prohibited in and out of competition and treated as a non-Specified Substance under the Code, meaning anti-doping sanctions apply regardless of whether a competition sample or out-of-competition test was positive.

What a Dutch reader should weigh

If you are based in the Netherlands and are researching TB-500, the regulatory picture is clear even if the clinical picture is not. No licensed Dutch pharmacy can lawfully supply TB-500, because it holds no marketing authorisation. No Dutch insurer will contribute to the cost. The Farmacotherapeutisch Kompas provides no prescribing guidance. The Geneesmiddelenwet (Medicines Act) requires authorisation before a product is placed on the market as a medicine, and TB-500 has not met that requirement. The product available to a Dutch consumer exists entirely outside the authorised medicines framework.

For the broader European and international regulatory picture, the TB-500 regulation section covers the EU, UK, US, Australia and other jurisdictions where we have verified the current status. The Dutch position is consistent with the broader EU position: no authorisation, no official pricing, no reimbursement pathway.

What we do not yet know

The core unknowns in this space are clinical rather than regulatory. We do not know whether the tissue-repair effects seen in rodent models translate to humans at any subcutaneous dose. We do not know what a human therapeutic window looks like for soft-tissue injury. We do not know the long-term safety profile, particularly given a tumorigenesis signal in some preclinical work linking Tβ4 to tumour growth and metastasis in certain cancer-cell models. And we do not know what a Dutch patient is actually receiving in a vial labelled TB-500 from a grey-market source, because independent identity testing is not a standard feature of that supply chain.

Until human trial data exists for the indications grey-market consumers use it for, the honest answer to the question of what TB-500 costs in the Netherlands is: no verified figure exists, and any vendor quoting a price is operating outside the Dutch medicines system. If you are considering any peptide for a health-related reason, the conversation belongs with a clinician who knows your medical history.